Author:
OncoTherics has signed a collaboration agreement with the University of Cambridge to progress a series of novel preclinical investigations using OCT1002 in Pancreatic Tumour models.
The investigations will augment OncoTherics formal preclinical studies, providing useful additional information about OCT1002 in Pancreatic Cancer.
OncoTherics is currently raising first round funding. If you are interested in taking part, please provide your contact details so that we can include you on our contact list.
Are you working on a project where OncoTherics' technology might be of help or would you like to collaborate in our research? Please provide your contact details so that we can include you on our contact list.